Nature Communications

Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial

• David Hsiehchen
• Radhika Kainthla
• Heather Kline
• Ellen Siglinsky
• Chul Ahn
• Hao Zhu

2025-07-01

Full text

DOI https://doi.org/10.1038/s41467-025-60757-7